Special Issue "Photodynamic and Photothermal Therapeutic Approaches in Health Care System"
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".
Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 397
Special Issue Editors
Interests: photodynamic therapy; biofilm; antimicrobial resistance; bacteria
Prof. Dr. Lothar Lilge
Special Issue Information
Dear Colleagues,
Photodynamic (PDT) and photothermal (PTT) therapies are promising approaches to treat cancer, and there are approved indications for prostate, bladder, brain and skin cancers. Moreover, studies have also shown the ability of PDT to cure microbial infections. PDT and PTT are minimally invasive therapies with approvals in some pathologies as well as unexploited potential in oncology and antimicrobial treatment. While PTT results in in situ protein denaturation and cellular coagulation, PDT exploits absorption by photosensitizers to generate reactive oxygen species. The development of new photosensitizers and formulations for PDT are urgently, such as innovative nanoparticle-based solutions that profoundly improve targeting and camouflage capability, solubility, biocompatibility, penetrability, light conversion efficiency, and PS circulation time. Novel ideas and nano tricks on bypassing biological barriers, reducing dosage and side effects, improving real-time monitoring of drug release and distribution, and maximizing PDT efficiency. As neither therapy target specific pathways, there is no known risk of the development of antimicrobial or cancer resistance post therapy. Photodynamic therapy has been used successfully for curing diseases such as age-related macular degeneration, rheumatoid arthritis, skin disease and arteriosclerosis. It is commonly used to treat precancerous cells, sun-damaged skin, and acne. Moreover, a regulated dose for a given time is observed as non-toxic. This Special Issue invites both original research articles and reviews, with a special focus on translational research towards the described topic. All submitted materials are subject to a rigorous peer-review process.
Prof. Dr. Asad Khan
Prof. Dr. Lothar Lilge
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- photodynamic therapy
- new photosensitizers and formulations
- antimicrobial ressiatnce
- topical infections
- skin cancer
- oral cancer
- photothermal
- ROS
